Acceleron Pharma, Inc. clinical trials

Acquired by Merck & Co., Inc, Nov 19, 2021 · source ↗

The registry lists 26 studies whose lead sponsor is Acceleron Pharma, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 26 of 26. All Merck & Co., Inc studies →

• A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)CompletedNCT04945460Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)TerminatedNCT04811092Phase 3

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)CompletedNCT04896008Phase 3

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)CompletedNCT04576988Phase 3

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Study of Sotatercept for the Treatment of Pulmonary Arterial HypertensionCompletedNCT03738150Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)CompletedNCT01749514Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)CompletedNCT02268383Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)CompletedNCT01749540Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)CompletedNCT02268409Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)TerminatedNCT04948554Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT03496207Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTerminatedNCT01099761Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell CarcinomaTerminatedNCT01727336Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedNCT01458392Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)TerminatedNCT02927080Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)TerminatedNCT03943290Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseTerminatedNCT03124459Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02024087Phase 1/2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Phase 1 Study of ACE-083 in Healthy SubjectsCompletedNCT02257489Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal WomenCompletedNCT00709540Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Study of ACE-2494 in Healthy SubjectsCompletedNCT03478319Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple MyelomaCompletedNCT00996957Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTerminatedNCT01239758Phase 2

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• Study of ACE-536 in Healthy Postmenopausal WomenCompletedNCT01432717Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal WomenCompletedNCT00952887Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc

• A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal VolunteersCompletedNCT00755638Phase 1

  Sponsor listed in the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · First submitted before Acceleron Pharma, Inc. became part of Merck & Co., Inc